Leadership

Victor Sloan, MD

Victor Sloan, MD, is a rheumatologist, pharmaceutical leader, and clinical developer known for nurturing pharmaceutical assets from ideation to commercialization. A skilled designer, implementer, and manager of early- and late-stage clinical trial programs, Dr. Sloan is a recognized expert on immunological and related disorders, with deep expertise in small molecules and biologics. He has extensive corporate and consulting experience, and is adept at collaborating with medical affairs, scientific, and business teams to deliver clinical and commercial success.

As Founder and Chief Executive Officer of Sheng Consulting, Dr. Sloan provides pharmaceutical firms with strategic and operational expertise for clinical development, regulatory agency interactions around the world, and advisory committee preparation and execution.

Before starting Sheng Consulting, Dr. Sloan held several leadership positions, including Therapeutic Area Head for Immunology at UCB, a €4.6B global pharmaceutical company focused on immunological and neurological disorders. At various times, he led all late-stage development efforts for immunology, including Cimzia®, the company’s flagship immunology product which at the time had 50+ ongoing trials in Phases 2 through 4. He also partnered with the Medical Affairs, Regulatory, Marketing, and Safety groups to enhance lifecycle management, and collaborated with the internal UCB New Medicines division to provide clinical expertise in the transition of early compounds to full development.

Earlier, Dr. Sloan was Vice President, Inflammation and Immunology (I&I) at Celgene Corporation, where he led late-stage drug development in the I&I business, including the design and implementation of 7 Phase 2 and 3 clinical trials in psoriatic arthritis, psoriasis, and rheumatoid arthritis (RA) within just 6 months. He previously served as Senior Vice President/Chief Medical Officer at Protalex, Inc. and as Disease Area Section Head, Arthritis at Novartis Pharmaceuticals Corporation.

As a consultant, Dr. Sloan provided strategic input to Kyowa Hakko Kirin Pharma for development of its lead biologic in autoimmune disease. He also consulted with Oncopath Genomics, a start-up diagnostic company, regarding development of its business plan, licensing, intellectual property, and funding strategies. In 2007, he was retained by UCB to help lead the filing for Cimzia®, including serving as the lead author for the clinical overview and providing strategic input to other parts of the BLA.

Dr. Sloan, a rheumatologist, has seen patients throughout his career and still volunteers weekly at the Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ, where he is Clinical Professor of Medicine. He is Board Certified in Rheumatology by the American Board of Internal Medicine and is licensed as a physician by the State of New Jersey. He is a Fellow of both the American College of Physicians and the American College of Rheumatology, and is a widely published author of peer-reviewed publications in both basic science and clinical research.

Dr. Sloan earned a diploma at the Belfer Institute for Advanced Biomedical Studies at the Albert Einstein College of Medicine, his MD degree at New York Medical College, and an AB in Biological Sciences at the University of Chicago.  He and his family live in Flemington, NJ.